
Assertio Holdings ASRT
$ 0.73
-3.54%
Quarterly report 2025-Q3
added 11-10-2025
Assertio Holdings Gross Profit 2011-2025 | ASRT
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Assertio Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 86.4 M | 220 M | 293 M | 308 M | 368 M | 275 M | 375 M | 127 M | 84.8 M | 127 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 375 M | 84.8 M | 227 M |
Gross Profit of other stocks in the Drug manufacturers industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Canopy Growth Corporation
CGC
|
79.5 M | $ 1.69 | -3.16 % | $ 182 M | ||
|
Alimera Sciences
ALIM
|
69.9 M | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
57.8 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-616 K | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-1.43 M | - | 0.86 % | $ 117 M | ||
|
Cronos Group
CRON
|
-25.8 M | $ 3.05 | -6.72 % | $ 1.63 B | ||
|
Agile Therapeutics
AGRX
|
10.6 M | - | 10.11 % | $ 58.2 M | ||
|
Aurora Cannabis
ACB
|
188 M | $ 5.17 | -4.22 % | $ 86.3 M | ||
|
Catalent
CTLT
|
953 M | - | - | $ 11.5 B | ||
|
HEXO Corp.
HEXO
|
-75.7 M | - | 2.45 % | $ 38.1 M | ||
|
DURECT Corporation
DRRX
|
25.4 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
135 M | - | -39.89 % | $ 27.7 M | ||
|
Organogenesis Holdings
ORGO
|
366 M | $ 4.78 | -0.83 % | $ 629 M | ||
|
Endo International plc
ENDP
|
1.35 B | - | - | $ 28.9 M | ||
|
Emergent BioSolutions
EBS
|
318 M | $ 12.03 | 5.34 % | $ 616 M | ||
|
Pacira BioSciences
PCRX
|
314 M | $ 26.7 | 1.56 % | $ 1.23 B | ||
|
Evoke Pharma
EVOK
|
-63.7 K | $ 10.97 | 0.18 % | $ 36.7 M | ||
|
Athenex
ATNX
|
26.7 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
154 M | $ 21.39 | 0.14 % | $ 2.04 B | ||
|
Rockwell Medical
RMTI
|
8.7 M | $ 0.87 | -5.71 % | $ 20.3 M | ||
|
Evolus
EOLS
|
182 M | $ 7.18 | 1.92 % | $ 445 M | ||
|
Harrow Health
HROW
|
90.6 M | $ 45.82 | -2.64 % | $ 1.49 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
5.46 M | $ 3.51 | -2.11 % | $ 4.36 M | ||
|
China Pharma Holdings
CPHI
|
-1.99 M | $ 1.55 | -0.26 % | $ 27.1 M | ||
|
Bausch Health Companies
BHC
|
6.25 B | $ 6.88 | -0.65 % | $ 2.51 B | ||
|
Veru
VERU
|
5.85 M | $ 2.44 | 0.83 % | $ 329 M | ||
|
Lannett Company
LCI
|
33.2 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
47.5 M | $ 1.8 | -6.51 % | $ 402 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
28.8 M | $ 3.05 | 20.47 % | $ 42.9 M | ||
|
cbdMD
YCBD
|
12 M | $ 1.39 | 13.52 % | $ 5.99 M | ||
|
PetIQ
PETQ
|
253 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
1.09 K | $ 4.32 | 6.4 % | $ 130 M | ||
|
Jupiter Wellness
JUPW
|
-2.45 M | - | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
1.54 B | $ 12.86 | -2.17 % | $ 1.77 B | ||
|
ProPhase Labs
PRPH
|
70.7 M | $ 0.12 | 0.17 % | $ 1.9 M | ||
|
Radius Health
RDUS
|
221 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
48.2 M | - | -4.76 % | $ 65.3 M | ||
|
Sundial Growers
SNDL
|
240 M | $ 1.96 | -11.31 % | $ 3.37 M | ||
|
OptiNose
OPTN
|
41.6 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
3.4 M | - | -27.8 % | $ 2.56 M | ||
|
SCYNEXIS
SCYX
|
3.58 M | $ 0.64 | -1.25 % | $ 30.6 M | ||
|
Tilray
TLRY
|
147 M | $ 11.6 | -4.56 % | $ 7.17 B | ||
|
TherapeuticsMD
TXMD
|
1.3 M | $ 1.69 | -3.43 % | $ 17.6 M | ||
|
Zomedica Corp.
ZOM
|
17.3 M | - | -0.21 % | $ 98 M | ||
|
Viatris
VTRS
|
6.5 B | $ 11.66 | 0.09 % | $ 14.1 B |